First as to conventional therapies:
1. Local/Locoregional Control
For brain metastases, whole brain radiotherapy (WBRT), as your oncologist appears to be suggesting, is certainly one choice.
Guidance: But you should discuss with your oncologist or with a referred to interventional radiologist the possible use of an alternative, that of stereotactic radiosurgery (SRS) - in the form of Gamma Knife, Cyberknife or LINAC forms, although Gamma Knife is the most common - which is especially attractive when brain disease is limited or the number of brain lesions is small, and to avoid the potential for neurocognitive decline that is sometimes associated with WBRT. In particular current consensus suggest that Gamma Knife (radio)surgery (GKS) appears to as effective as surgical tumor resection (level I evidence, the highest), avoiding the impairments in cognition and quality of life that can be a consequence of WBRT (level I evidence), with high local efficacy, preservation of cerebral functions, short hospitalization and the option to continue systemic chemotherapy at the same time, all being factors in favor of this minimally invasive stereotactic radiosurgery (SRS) approach, and SRS can be later, if necessary, combined with WBRT. Of course every case and patient is unique, but this option should be explored further to discuss its viability for you.
2. Systemic Therapy: Targeting both Extracranial and Cranial Disease
Systemic therapy remains the mainstay of treatment whenever there is extracranial involvement (to other viscera or organs, like lung or liver, or to the bone). To date you have had EC/T (epirubicin + cyclophosphamide / paclitaxel (Taxol)), but it remains to be determined whether you've been exposed to the PARP inhibitor veliparib under the BROCADE clinical trial (carboplatin + paclitaxel (Taxol) + veliparib), veliparib being a good choice for your case of BRCA1-positivity.
However once there is CNS (brain and/or leptomeningeal) involvement, the most promising therapeutic agents are those that can cross the blood-brain barrier (BBB) in order to be effective both in extracranial (lung, liver, bone) as well as CNS disease, and these are reviewed extensively in my paper CNS Metastasis from Breast Cancer – New Promise: A Review (at: https://www.researchgate.net/publication/232754712_CNS_Metastasis_from_Breast_Cancer__New_Promise_A_Review).
Of all of the cross-BBB agents, capecitabine (Xeloda) has been the most extensively studied, and of confirmed benefit in breast cancer brain metastases. To add further cross-BBB anti-metastatic activity, capecitabine (Xeloda) is often combined with temozolomide (TMZ), in dosage and schedule as detailed in my review.
Bone metastasis have their own special protocols, which always involve either a bisphosphonate, namely zoledronic acid (Zometa) or the RANKL inhibitor denosumab (Prolia/Xgeva), and both are good choices, and switchable when or if needed.
Guidance: There are more cross-BBB chemotherapies such as vinorelbine (Navelbine) and cisplatin, among several others (including liposomal doxorubicin (Doxil/Caelyx) and possibly also bevacizumab (Avastin)), so many options exist as fallback should they be needed after a trial of X-TMZ (capecitabine (Xeloda) + temozolomide (TMZ)). But given the known efficacy of capecitabine (Xeloda) w/wo temozolomide (TMZ), I would strongly advise exploring this option first with your oncologist.
3. Complementary and Alternative Medicine (CAM) Modalities
First, as to the CAM agents you enumerated commonly used in Germany, only standardized mistletoe extract in the form of the commercial product Helixor, has any robust human clinical evidence of potential benefit, with one prospective randomized controlled clinical trial (Piao and colleagues at Universitåt zu Köln, Anticancer Res 2004) plus a strong systematic review of controlled clinical studies (Kienle and Kiene, Freiburg, Integr Cancer Ther June 2010) which also conclude that it beneficially reduces the side-effects of conventional therapies (both chemotherapy and radiation therapy) in cancer patients and thus improves quality of life (QoL). The others lack sufficient robust evidence of benefit to make any recommendations.
Guidance: As to the other CAM interventions you mention you are on, here's my commentary, inline (in brackets) with your original text), but please consult my latest guidelines in my Edge-CAM regimen (version 4, here on No Surrender, at: http://www.nosurrenderbreastcancersupportforum.com/post/edgecam-v-4-0-62413-6399492?goto=lastpost):
In addition I am taking Vitamin D3: I increased my daily dose to 4000 IE/day, since my recent blood serum levels are only at about 30ng/ml.
[EDGE Commentary: the goal is to take sufficient supplemental Vitamin D3 to achieve a threshold of at least ~66 ng/ml, so no one amount is right, but rather your Vitamin D levels have to be retested to assure that that level is obtained, as I document in the Edge-CAM regimen]
I am taking calcium as well, as calcium acetate 500mg/day, but I read that you preferably suggest calcium phosphate. I am drinking at least 5 cups of japanese green tea every day (mainly gyokuro and sencha), brewing it for 8-10 minutes. However, I'm not sure if this is enough to absorb sufficient amounts of EGCG.
[EDGE Commentary: it's generally infeasible to be able to achieve the optimal level of EGCG polyphenols through consumption of dietary green tea, and in any case the dose delivered would not be standardized on active content, which is required for optimal activity, so supplementation with a standardized green tea extract is needed.]
The same applies to curcumin and turmeric, which I use as a spice daily, in combination with black pepper.
[EDGE Commentary: ditto here; it's just impossible to achieve to highly precisely, certified, standardization of active curcuminoid components by other than supplemental, not dietary, consumption.]
I am supplementing with freeze dried broccoli sprouts (I cannot stand kale and other cruciferous vegetables) and I am eating a mediterranean diet with lots of vegetables, low glycemic fruit, whole grains, fish, meat occasionally (especially white meat), avoiding any added sugar.
[EDGE Commentary: this is a good regimen (I am not a fan of broccoli sprouts and do not believe there is sufficient evidence of benefit to warrant any recommendation, but modest consumption may be without significant harm). Remember to assure optimal olive oil consumption (about 4 tablespoons daily).]
I'm very confused about dairy (no dairy versus low-fat dairy or produce from grass-fed animals, sheep and goat's milk versus cow's milk), but I also know that I have to gain weight (I'm currently a little underweight) and probably need extra protein and fat.
[EDGE Commentary: the latest systematic reviews suggest that it is intake of high-fat dairy, but not low-fat dairy, that is associated with a higher risk of mortality after breast cancer diagnosis (Kroenke et al., JNCI 2013). Therefore moderate consumption of skim or low-fat milk or yogurt should be unproblematic.
Guidance: But better still is to shift to soy consumption, which the evidence now clearly establishes as beneficial to breast cancer, but some amount of low-fat dairy can be support.]
I also started to do strength training. Before diagnosis I loved to run, but my actual lung capacity doesn't let me!
Guidance: The best physical exercise for anticancer benefit is a mixture of strength (resistance) plus aerobic exercise, and the aerobic exercise can be as simple as walking in place at home holding 5 - 10 pound weights in each hand, swinging arms as you walk in place. Although running may be good, most often it isn't, as many people run in urban areas where the increase in respiration almost always assure unfavorable high consumption of air-borne pollutants and carcinogens.]
Guidance: Consult the Edge-CAM regimen recommendations, as well as the lifestyle recommendations that accompany it.
Final Advice: the above is a lot of material to digest, but worth the effort, as is also having some candid discussions with your oncology concerning the options I raised above in terms of conventional therapies, and I would add also that a second opinion is almost always advisable and of benefit. Finally, in the unlikely event that the optimal therapeutics still allow for disease progression, at that time we can consider evaluating potential clinical trials, but for now, you have many promising options to choose from.
And as always, I am here for any further questions you may have.
Kind regards, and best fortune to you.
Director, Medical Research,
No Surrender Breast cancer Foundation (NSBCF)